Macrogenics Inc

NASDAQ:MGNX   3:59:51 PM EDT
19.53
+0.48 (+2.52%)
Products

MacroGenics Announces FDA Approval Of Margenza For Patients With Pretreated Metastatic Her2-Positive Breast Cancer

Published: 12/16/2020 21:51 GMT
Macrogenics Inc (MGNX) - Macrogenics Announces FDA Approval of Margenza™ for Patients With Pretreated Metastatic Her2-positive Breast Cancer.
Macrogenics Inc - Product Launch Anticipated in March of 2021.
Macrogenics Inc - Macrogenics Anticipates That Margenza Will Be Available in March of 2021.